首頁 > 市場調查報告書 > 製藥

呼吸器

市場調查報告書

商品編碼

2052755

特發性肺纖維化市場：依藥物、給藥途徑、通路及地區分類

Idiopathic Pulmonary Fibrosis Market, By Drug, By Route of Administration, By Distribution Channel, and By Geography

出版日期: 2026年03月31日 | 出版商:

Coherent Market Insights | 英文 152 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2026年特發性肺纖維化市場規模估計為53.906億美元，預計2033年將達到97.91億美元。預計2026年至2033年，該市場將以8.9%的複合年成長率成長。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	53.906億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	8.90%	2033年市場規模預測：	97.91億美元

特發性肺纖維化（IPF）是一種間質性肺炎，其特徵是病因不明的慢性進行性纖維化，主要發生於老年人的肺部，並伴隨典型間質性肺炎（UIP）的組織病理學和/或放射學觀察。 IPF的診斷需要排除其他類型的間質性肺炎，包括其他類型的特發性間質性肺炎（IIP）以及與環境暴露、藥物或結締組織疾病相關的間質性肺病（ILD）。

市場動態

特發性肺纖維化盛行率的不斷上升預計將推動市場成長。例如，根據美國國家醫學圖書館2022年7月發布的報告，2021年全球特發性肺纖維化的盛行率為每10萬人中有13至20例。 2021年，美國約有10萬人受此影響，每年新增確診病例3萬至4萬例。

根據美國國家生物技術資訊中心 (NCBI) 發布的報告，截至 2022 年，印度特發性肺纖維化的盛行率約為 13.7%。

此外，隨著特發性肺纖維化盛行率的不斷上升，主要市場參與者正致力於推出新產品，預計這將推動預測期內的市場成長。例如，2022年5月，全球領先的學名藥山德士宣佈在美國推出Pirfenidone，這是首個AB級（抗體）學名藥，與基因泰克公司的Esbury具有完全替代性，用於治療特發性肺纖維化（IPF）患者。這種口服藥物將透過專科藥房開立處方給患者。

本次調查的主要特點

本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
此外，本研究還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要參與者採取的競爭策略的重要見解。
本研究基於以下參數，對全球特發性肺纖維化市場的主要參與者進行了概況分析：公司亮點、產品系列、關鍵特性、財務績效和策略。本研究涵蓋的主要參與者包括：基因泰克（Genentech）、勃林格殷格翰國際（Boehringer Ingelheim International）、Avalin Pharma、Astra Zeneca）、Blade Therapeutics、百時美施貴寶（Bristol-Myers Squibb）、西普拉（Cipla）、羅氏（F. Hitaco）、羅氏（Cipakla）、羅氏（Cipakla）、羅氏（Cipilla）、羅氏） NV、Medicinova、默克（Merck & Co.）、Promedioll、Prometic Life Sciences、Okuma Pharmaceutical (India) Private Limited、山德士國際有限公司（諾華）（Sandoz International GmbH (Novartis)）和Algernon Pharmaceuticals。
本報告中的見解將使各公司的行銷負責人和經營團隊能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
全球特發性肺纖維化市場報告的目標受群眾外包括該行業的各類相關人員，例如投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
透過分析全球特發性肺纖維化市場中使用的各種策略矩陣，相關人員將能夠更輕鬆地做出決策。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太國家
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 北非
- 中非
- 南非

第8章競爭情勢

Genentech, Inc.
Boehringer Ingelheim International GmbH.
Avalyn Pharma, Inc.
AstraZeneca
Blade Therapeutics
Bristol-Myers Squibb Company
Cipla Inc.
F. Hoffmann-La Roche
FibroGen, Inc.
Galapagos NV
MediciNova, Inc.
Merck & Co., Inc.
Promedior, Inc.
Prometic Life Sciences Inc.
Daewoong Pharmaceutical（India）Pvt Ltd.
Sandoz International GmbH（Novartis）
Algernon Pharmaceuticals Inc.

第9章

調查方法
關於本公司

簡介目錄

Product Code: CMI2466

Idiopathic Pulmonary Fibrosis Market is estimated to be valued at USD 5,390.6 Mn in 2026 and is expected to reach USD 9,791.0 Mn by 2033, growing at a compound annual growth rate (CAGR) of 8.9% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 5,390.6 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	8.90%	2033 Value Projection:	USD 9,791 Mn

Idiopathic pulmonary fibrosis (IPF) is a specific form of chronic, progressive fibrosing interstitial pneumonia of unknown cause that occurs primarily in older adults, in the lungs, and is associated with the histopathologic and/or radiologic pattern of usual interstitial pneumonia (UIP). The diagnosis of IPF requires exclusion of other forms of interstitial pneumonia including other idiopathic interstitial pneumonias (IIP) and interstitial lung disease (ILD) associated with environmental exposure, medication, or connective tissue disease.

Market Dynamics

Increasing prevalence of Idiopathic pulmonary fibrosis is expected to drive the market growth. For instance, in July 2022, according to the report published by National Library of Medicine, the prevelance of idiopathic pulmonary fibrosis was 13 to 20 per 100,000 people worldwide in 2021. About 100,000 people were affected in the U.S., in 2021, whereas 30,000 to 40,000 new cases are diagnosed every year.

According to the report published by National Center for Biotechnology Information, the prevalence of Idiopathic pulmonary fibrosis in India was found to be approximately 13.7% in 2022.

Furthermore, due to increasing prevalence of Idiopathic pulmonary fibrosis, the key market players are focusing on new product launches, and this is expected to drive the market growth over the forecast period. For instance, in May 2022, Sandoz, a global leader in generic and biosimilar medicines, announced the launch of its generic Pirfenidone in the U.S., the first AB-rated (Antibody)(fully substitutable) equivalent to Genentech's, a biotechnology company, Esbriet, to treat patients with idiopathic pulmonary fibrosis (IPF). This oral medicine is prescribed to patients via specialty pharmacies.

Key features of the study

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global Idiopathic pulmonary fibrosis market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies Key companies covered as a part of this study include Genentech, Inc., Boehringer Ingelheim International GmbH, Avalyn Pharma, Inc., AstraZeneca, Blade Therapeutics, Bristol-Myers Squibb Company, Cipla Inc., F. Hoffmann-La Roche, FibroGen, Inc., Galapagos NV, MediciNova, Inc., Merck & Co., Inc., Promedior, Inc., Prometic Life Sciences Inc., Daewoong Pharmaceutical (India) Pvt Ltd, Sandoz International GmbH (Novartis), and Algernon Pharmaceuticals Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
Global Idiopathic pulmonary fibrosis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Idiopathic pulmonary fibrosis market.

Market Segmentation

Global Idiopathic pulmonary fibrosis market, By Drug (Revenue, USD Mn, 2021 - 2033)
Pirfenidone
Nintedanib
Others (Interferon gamma-1b and Others)
Global Idiopathic pulmonary fibrosis market, By Route of Administration (Revenue, USD Mn, 2021 - 2033)
Oral
Parenteral
Global Idiopathic pulmonary fibrosis market, By Distribution Channel (Revenue, USD Mn, 2021 - 2033)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Idiopathic pulmonary fibrosis market, By Region (Revenue, USD Mn, 2021 - 2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC Countries
- Israel
- Rest of Middle East
Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
Genentech, Inc.
Boehringer Ingelheim International GmbH
Avalyn Pharma, Inc.
AstraZeneca
Blade Therapeutics
Bristol-Myers Squibb Company
Cipla Inc.
Hoffmann-La Roche
FibroGen, Inc.
Galapagos NV
MediciNova, Inc.
Merck & Co., Inc.
Promedior, Inc.
Prometic Life Sciences Inc.
Daewoong Pharmaceutical (India) Pvt Ltd.
Sandoz International GmbH (Novartis)
Algernon Pharmaceuticals Inc.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Attractiveness Analysis
- Market Opportunities
- Product Launches
- Merger, Acquisition, Collaboration
- Regulatory Guideline and Compliances
- Key Developments
- Market Trends
- PEST Analysis
- Epidemiology
- PORTER's Analysis
- Regulatory Scenario
- Brand Analysis
- Pricing Analysis
- Pipeline Analysis

4. Global Idiopathic Pulmonary Fibrosis Market, By Drug, 2021 - 2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Pirfenidone
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Nintedanib
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Others (Interferon gamma-1b and Others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

5. Global Idiopathic Pulmonary Fibrosis Market, By Route of Administration, 2021 - 2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

6. Global Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, 2021 - 2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segments Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

7. Global Idiopathic Pulmonary Fibrosis Market, By Region, 2021 - 2033, (USD Mn)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Region, 2021 - 2033
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-Region, 2021 - 2033, (USD Mn)
  - North Africa
  - Central Africa
  - South Africa

8. Competitive Landscape

Genentech, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Boehringer Ingelheim International GmbH.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Avalyn Pharma, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
AstraZeneca
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Blade Therapeutics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Bristol-Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Cipla Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
F. Hoffmann-La Roche
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
FibroGen, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Galapagos NV
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
MediciNova, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Promedior, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Prometic Life Sciences Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Daewoong Pharmaceutical (India) Pvt Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Sandoz International GmbH (Novartis)
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Algernon Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies